Replies to post #770897 on NorthWest Biotherapeutics Inc (NWBO)

[beartrap12]

More from the publication this month of Eden 2.0 technology that Danish Dude posted. This portion addresses Eden readiness and validation for use.

? The Reality: A Direct Counter
1. From Prototype to Production-Ready Hardware: The claim that units
haven't been ordered is factually incorrect. NWBO has officially moved
beyond the R&D phase and engaged a specialized engineering contractor
to fabricate commercial-grade, GMP-compliant Flaskworks instrument
units. This is the tangible step of turning a design into licensable
manufacturing hardware.

2. Validation with a Respected Third Party: NWBO is collaborating with
Advent BioServices, a well-regarded contract development and
manufacturing organization (CDMO), to perform the final validation runs on
these GMP units. A CDMO's involvement provides independent, expert
validation and is a standard and crucial step in generating the definitive data
package required for regulatory filings. This process is actively underway.

3. The "Substantial Comparability" Milestone: The company has confirmed
that the DCVax-L product manufactured by the Flaskworks system is
"substantially comparable" to the product from the prior manual process.
This is a vital de-risking event. For regulators like the MHRA and FDA, who
encourage automation, it means the new manufacturing method does not
negatively alter the final therapeutic product, which greatly simplifies and
shortens the pathway to full regulatory approval.